Kornimate/medical-research-clean huggingface dataset:
evaluating the effectiveness of implementation intentions to strengthen approach-avoidance training

Conditions: Alcohol Use Disorder

Summary: approach bias modifcation corresponds to computerized interventions designed to change a cognitive bias (i.e., the approach bias) that may contribute to the maintenance of alcohol use disorder. this study aims to compare the effectiveness of a classical approach bias modification program, an approach bias modification program integrating a planning strategy (i.e., implementation intentions) and a sham-training to decrease the approach bias (from pre to post-test), and alcohol use disorder symptomatology (from baseline to follow-up). 112 patients will be recruited for this study.

the approach bias is considered to be a maintenance factor of alcohol use disorder. it correspond to the relative ease to approach alcohol rather than to avoid it. approach bias modifcation correspond to computerized interventiond designed to change it by training participants to emit avoidance response (e.g., pull the joystick away) toward alcohol stimuli (e.g., alcohol pictures). those programs have shown their effectiveness to promote abstinence among alcohol use disorder patients. this study aims to compare the effectiveness of a classical approach bias modification program to the one of a similar program integrating a planning add-on strategy named implementation intentions and to a sham-training. 112 patients will be recruited for this study at clinic de la mitterie rehab center. during their hospitalization, participants will have to complete: a baseline that assess alcohol use disorder symptomatology (i.e., alcohol consumption, alcohol consumption, and alcohol-related consequences) and other alcohol-related variables (e.g., motivation and self-efficacy), a pre-test that assess the approach bias, 6 sessions of one of the three experimental interventions {classical approach bias modification, approach bias modification with implementation intentions, sham-training}, and a post-test that reassess the approach bias. after their hospitalization, they will have to complete a 2, 4 and 6-month online follow-up that reasses alcohol use disorder symptomatology. it is expect that the approach bias modification program with implementation intentions will decrease the approach bias and alcohol use disorder symptomatology more than the classical program, that will also decrease it more than the sham-training.

Eligibility criteria:
inclusion criteria: * care at the clinic for alcohol use disorder, * have an e-mail address, * written and spoken french, * signing informed consent. exclusion criteria: * not currently remissioned for the alcohol use disorder, * no other substance use disorder (except tobaco one)

Keywords: cognitive bias alcohol use disorder
lens fitting evaluation of coopervision myday™ compared with 1-day acuvue® trueye® and dailies total1®

Conditions: Myopia

Summary: lens fitting evaluation of coopervision myday™ compared with 1-day acuvue® trueye® and dailies total1®

the aim of this non-dispensing study is to evaluate the fitting performance of myday™ 8.4 base curve, especially for flatter corneas, and compared it with 1-day acuvue® trueye® 9.0 base curve and dailies total1® 8.8 base curve in a range of spherical powers.

Eligibility criteria:
inclusion criteria: * is between 18 and 40 years of age (inclusive) * has had a self-reported visual exam in the last two years * is an adapted soft spherical contact lens wearer * has a contact lens spherical prescription between -4.00 to - 6.00 and higher than -7.00d (diopters) (inclusive) * has a bfs (best fit sphere) that is higher than 8.2 measured and calculated by corneal topography * can achieve best corrected spectacle distance visual acuity of 20/25 (0.10 logmar) or better in each eye * can achieve a distance visual acuity of 20/30 (0.18 logmar) or better in each eye with the study contact lenses * has clear corneas and no active ocular disease * has read, understood and signed the information consent letter * patient contact lens refraction should fit within the available parameters of the study lenses * is willing to comply with the wear schedule * is willing to comply with the visit schedule exclusion criteria: * is not a habitual wearer of soft spherical contact lenses * has a contact lens prescription outside the range of the available parameters of the study lenses * has a contact lens prescription outside the range of the inclusion power range * has a spectacle cylinder ≥1.00d of cylinder in either eye * has a history of not achieving comfortable contact lens wear (5 days per week; \> 8 hours/day) * has contact lens best corrected distance vision worse than 20/25 (0.10 logmar) in either eye * presence of clinically significant (grade \> 2) anterior segment abnormalities * presence of ocular or systemic disease or need of medications which might interfere with contact lens wear * slit lamp findings that would contraindicate contact lens wear such as: * moderate to severe dry eye * pterygium, pinguecula, or corneal scars within the visual axis * neovascularization \> 0.75 mm in from of the limbus * giant papillary conjunctivitis (gcp) worse than grade 1 * anterior uveitis or iritis (past or present) * seborrheic eczema, seborrheic conjunctivitis * history of corneal ulcers or fungal infections * poor personal hygiene * has a known history of corneal hypoesthesia (reduced corneal sensitivity) * has aphakia, keratoconus or a highly irregular cornea * has presbyopia or has dependence on spectacles for near work over the contact lenses * has undergone corneal refractive surgery * is participating in any other type of eye related clinical or research study
precision retrospective integrative study for metastatic lymph nodes in breast cancer

Conditions: Breast Cancer

Summary: accurate assessment of axillary lymph nodes in patients with breast cancer is essential for prognosis and treatment planning. staging and surgical management have evolved from axillary lymph node dissection to sentinel lymph node biopsy to minimize morbidity. however, sentinel lymph node biopsy has non-negligible morbidity, and more than 70% of biopsies are negative, calling into question its routine use. magnetic resonance imaging (mri) can be used to detect and stage lymph node metastases in situ, but its sensitivity and specificity are moderate to poor. few studies have employed artificial intelligence to detect lymph node metastases on mri images, and none have used an integrative multidata approach (ima), defined as modeling the combination of clinical and laboratory data with multiparametric mri. the primary objective of this retrospective observational study is to improve the accuracy of detecting lymph node involvement in breast cancer using ima. the secondary objective is to allow longitudinal monitoring of the effects of neoadjuvant therapy on lymph node involvement


Eligibility criteria:
inclusion criteria: * patients diagnosed with breast cancer who underwent mri and biopsy or surgery of axillary lymph nodes as part of their diagnosis and treatment * patients of all genders, ages, and stage i-iii of breast cancer * patients who underwent neoadjuvant therapy and have longitudinal imaging data available for analysis (for secondary outcome analysis) exclusion criteria: * patients whose mri images were of insufficient quality for analysis * patients who had a previous history of breast cancer * patients with a history of axillary surgery or lymph node dissection prior to the current diagnosis of breast cancer * patients who received neoadjuvant therapy at another institution
comparison erect spine in cardiac surgery

Conditions: Spine Erector; Cardiac Surgery; Acute Pain; Chronic Pain

Summary: open cardiac surgeries are characterized by the increased use of opioids and longer extubation times, being post-sternotomy pain one of the causes of greater patient discomfort, plexus blockages have been used more frequently given the good results of anatomical studies and case series that are just beginning to be published. however, there is not enough data to convince the scientific community of its advantages, continuing to carry out its performance due to lack of evidence. dexamethasone also shows an excellent result blocking the inflammatory chain and it was evidenced that it prolongs the time of blockages when used perineurally in the plexus blockages. this study wants to show the improvement of pain in patients who undergo this type of surgery and also show the advantages of a longer blockage, which can reduce use of analgesic and opioids, as well as decrease the time of hospitalization this is a double-blinded, randomized, clinical trial designed to determine the efficacy of spine erector whit dexamethasone gives more duration of the blockage and less pain after cardiac surgery.

evaluation of acute pain pos cardiac surgery in patients that who were subjected at myocardial revascularization. we offer espine erector block (esp) with linear array transducer and needle 100mm bilateral as a technique that offer results more hopeful and less invasive in patients with open cardiac surgery. favoring the implementation of fastrack anesthesia techniques in cardiac surgery and minimizing complications in this group of patients

Eligibility criteria:
inclusion criteria: * coronary artery bypass graft with cardiopulmonary bypass * left ventricular ejection fraction ≥ 45% exclusion criteria: * reoperation * low cardiac output syndrome * preoperative coagulopathy * presence of ventricular assist device other than intraaortic ballon pump * emergency procedures * bacterial or fungal infection in the preceding 30 days * active neoplasia * allergy or intolerance to steroids * allergy to ropivacaine * patient refusal * participation in other study

Keywords: spine erector cardiac surgery coronary arterial bypass surgery acute pain ropivacaine dexamethasone
nsaid vs steroid in trabeculectomy wound management

Conditions: Glaucoma

Summary: this study will examine the efficacy of steroid vs nsaid treatment in relation to trabeculectomy wound management. eligible study participants will be randomized to receive either steroid or nsaid topical treatment one week post-trabeculectomy. each group will dose with their assigned study treatment until three months post-trabeculectomy. study participants will be followed for twelve months post-trabeculectomy.


Eligibility criteria:
inclusion criteria: * adult patients over the age of 18 years * uncontrolled open angle glaucoma * scheduled to undergo stand-alone trabeculectomy * no previous incisional glaucoma surgery * no ocular surgery of any kind in prior 6 months exclusion criteria: * steroids and/or nsaids contraindicated * poor corneal epithelial health
comparative efficacy and safety study of gp2015 and enbrel® in patients with rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: demonstrate equivalent efficacy of gp2015 and eu-authorized enbrel in patients with moderate to severe, active (ra) who had an inadequate response to disease modifying anti-rheumatic drugs (dmard) including methotrexate (mtx).

demonstrate equivalent efficacy of gp2015 and eu-authorized enbrel in patients with moderate to severe, active (ra) who had an inadequate response to disease modifying anti-rheumatic drugs (dmard) including methotrexate (mtx). in addition, data on the safety profiles of both products, including immunogenicity and local tolerability at the injection sites, will be collected and compared. an additional study objective is to identify any potential risk of the transition from enbrel to gp2015 in terms of general safety and immunogenicity in ra patients

Eligibility criteria:
inclusion criteria: * patients at least 18 years of age with ra diagnosis according to acr 1987 or acr/eular 20110 criteria \>/= 6 months at the time of baseline visit * patient must have active disease defined as das28-crp\>/=3.2 * patients must have crp level above uln \>5mg/l) or erythrocyte sedimentation rate (esr) \>/=28mm/h * patients must have inadequate clinical response to mtx at a dose of 10-25 mg/wk after proper dose escalation according to local standards exclusion criteria: * previous exposure to etanercept in the past * patients with functional status class iv according to the acr 1991 revised criteria * history of active tuberculosis (tb) or presence of latent (inactive)tb detected by imaging and/or by the quantiferon-tb gold test at screening

Keywords: biosimilars rheumatoid arthritis etanercept
comparison of the surgical drain placement with use of kinesiologic tape

Conditions: Impacted Third Molar Tooth

Summary: the investigator's purpose was to compare the effects of the surgical drain and kinesiologic tape applications on postoperative morbidity after mandibular third molar surgery.

a total of 90 patients will be scheduled for impacted third molar surgery. the patients will be divided into 3 groups.all surgeries will be carried out by the same surgeon. group a will be treated with kinesiologic tape, group b will be treated with a surgical drainage tube and group c will be control group. after surgery in control group, routine surgical extraction will be performed.the investigators will compare postoperative pain, swelling, trismus and patients' comfort. the duration of each procedure from the start of the incision to the time of last suture placement will be noted. patients are recalled on days 2, 7, 14 postoperative pain, facial swelling, maximum mouth opening, wound dehiscence. for the assesment of the pain, visual analog scale will be used. for the swelling evaluation, measurement will be done from the different three region on the face: * tragus-pogonion * tragus-labial commissura * angulus mandible-lateral canthus maximum mouth opening will be noted before and after (one week later) the surgery.

Eligibility criteria:
inclusion criteria: * older than 18 of age, * asymptomatic bilateral mesioangular impacted mandibular third molar (pell and gregory class ii, position b) * fully covered with mucosa and bone exclusion criteria: * alcohol abuse, * smoking, * pregnancy, * no allergy * presence of acute severe periodontitis.

Keywords: kinesiology tape surgical drain pain swelling trismus
clinic-based and technology-supported sleep intervention for pediatric epilepsy

Conditions: Epilepsy

Summary: sleep problems are more common and more severe in children with epilepsy. the purpose of this study is to develop and evaluate the effect of a clinic-based and technology-supported sleep intervention for improving sleep and health in children with epilepsy and their parents.

participants in the intervention group will receive a standard pediatric neurology care plus a hybrid in-person and digital sleep education program.

Eligibility criteria:
inclusion criteria: * children aged between 1.5 and 9 years with a confirmed diagnosis of epilepsy. * parents with sufficient chinese language skills to fully comprehend the trial and complete questionnaires. exclusion criteria: * children with cerebral palsy or those who are bedridden. * children with a documented sleep disorder, such as obstructive or central sleep apnea and sleep-related movement disorders * children born with a congenital, genetic, or orthopedic abnormality that limit their activities of daily living or impair their physical activity.
mapping the human hiv chronobiome

Conditions: Hiv; Healthy

Summary: individuals infected with hiv have a high risk of developing metabolic comorbidities not traditionally associated with the immune dysregulation and deficiency associated with hiv infection and aids. many of these comorbidities in hiv uninfected individuals have been linked to a disordered circadian clock function. the study investigators will further evaluate the circadian clock in hiv infection as a mechanism underlying the metabolic dysregulation in this population.


Eligibility criteria:
inclusion criteria: * cohort 1: diagnosis of hiv infection with cd4+ counts \<500 cells/mm3 while untreated; * cohort 2: diagnosis of hiv infection with cd4+ counts \<300 cells/mm3 on arv; * cohort 3: volunteers must be in good health as based on medical history, physical examination, vital signs, and laboratory tests as deemed by pi; * volunteers are capable of giving informed consent; * 25-50 years of age; * own a smartphone which installs the remote sensing applications; * non-smoking; * male subjects only if feasible during recruitment; and * in case female volunteers are invited to enroll: non-pregnant, female subjects must consent to a urine pregnancy test. * females of child bearing potential will be asked to use a medically accepted method of birth control (such as oral contraceptives, intra-uterine device (iud), or condom with spermicide) while you participate in the study. * the use of contraception will not be required for male participants. exclusion criteria: * recent travel across more than two (2) time zones (within the past month); * planned travel across more than two (2) time zones during the planned study activities; * volunteers with irregular work hours, e.g. night shifts or becoming a parent; * use of illicit drugs; * high dose vitamins (vitamin a, vitamin c, vitamin e, beta carotene, folic acid and selenium), alcohol and any over-the counter nsaid in the (2) two weeks before the start of the 48 hour deep phenotyping period (females who are taking birth control pills can continue so for the duration of this study).; * history of abdominal surgery; * subjects, who have received an experimental drug, used an experimental medical device within 30 days prior to screening, or who gave a blood donation of ≥ one pint within 8 weeks prior to screening; * subjects with any abnormal laboratory value or physical finding that according to the investigator may interfere with interpretation of the study results, be indicative of an underlying disease state, or compromise the safety of a potential subject. * women who are breastfeeding.
renal replacement therapy in neonates

Conditions: Renal Failure

Summary: the circumstances for setting up dialysis in the neonatal period are multiple: congenital anomaly of the kidney and urinary tract (cakut), secondary acute renal failure whose etiologies are multiple (sepsis, hypovolemia, respiratory distress syndrome, neonatal asphyxia, arterial or venous renal thrombosis, nephrotoxic drugs, etc.), metabolic diseases (mainly hyperammonemia and leucinosis) and post-operative management of heart disease: analysis of the characteristics of the patients in our study and comparison with existing epidemiological data in the literature. the decision to set up dialysis in a newborn whose recovery of renal function is uncertain or in a context of acute multi-visceral failure is not always obvious and must be discussed carefully. multidisciplinary in connection with neonatologists, resuscitators and nephrologists as well as families with the consideration of the future quality of life of the child.


Eligibility criteria:
inclusion criteria: * minor under 28 days old * having benefited from a renal purification technique in the pediatric intensive care unit of the university hospital of strasbourg * holders of parental authority who do not object to the reuse of their child's data for scientific research purposes. exclusion criteria: - holders of parental authority who have expressed their opposition to the reuse of their child's data for scientific research purposes.

Keywords: neonatal dialysis extra-renal purification neonatal resuscitation
study to assess the safety, pharmacokinetics, and efficacy of baloxavir marboxil in chinese pediatric participants 1 to <12 years of age with influenza symptoms

Conditions: Influenza

Summary: the purpose of this study is to evaluate the safety of a single dose baloxavir marboxil compared with 5 days of oseltamivir administered twice a day (bid) in chinese pediatric participants aged 1 to \< 12 years with influenza symptoms.


Eligibility criteria:
inclusion criteria: * a participant who has a diagnosis of influenza virus infection and meets all the following conditions: * fever ≥ 38°c (tympanic temperature) at screening * at least one of the respiratory symptoms of influenza virus infection * a rapid influenza diagnostic test (ridt) or polymerase chain reaction (pcr) shows positive for influenza a/b, e.g., point-of-care/local laboratory results with use of nasal aspirate, throat swab, or nasal drip/droplet (or other appropriate sample) * the time interval between the onset of symptoms and screening is ≤ 48 hours * pcr (-) or antigen test (-) for severe acute respiratory virus-coronavirus 2 (sars-cov-2) using point-of-care/local laboratory test with nasal aspirate, throat swab, or nasal drip/droplet (or other appropriate sample) exclusion criteria: * a participant having severe influenza virus infection symptoms requiring inpatient treatment * received systemic corticosteroid or immunosuppressive therapy * primary immunodeficiency syndrome * history of organ transplantation * human immunodeficiency virus (hiv) infection * immunization with a live/attenuated influenza vaccine in 2 weeks prior to randomization * previous malignancy within the last 5 years or has an active cancer at any site * a participant who received any medications with anti-flu effect such as baloxavir, peramivir, oseltamivir, zanamivir, favipiravir, arbidol, amantadine or traditional chinese anti-influenza medicines within 30 days before screening * diagnosed with or suspected sars-cov-2 infection, or close contacts of diagnosed or suspected sars-cov-2 infected patients * severe underlying disease or condition potentially affecting study evaluation in the opinion of the investigator/sub-investigator * a participant who received an investigational or unapproved drug product within 30 days or 5 x the half-life before screening, whichever is longer
rituximab plus lenalidomide in patients with mucosa associated lymphoid tissue

Conditions: Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT)

Summary: this is an open label, phase ii study to evaluate the capacity of rituximab (mabthera®) plus lenalidomide (revlimid®) to induce objective responses in patients with mucosa associated lymphoid tissue (malt) lymphoma presenting with measurable disease.


Eligibility criteria:
inclusion criteria selected: * histologically verified diagnosis if malt lymphoma of any localization * measurable disease upon diagnosis or first or greater relapse after local therapy, prior chemotherapy orhp-eradication. in addition, also in patients with gastric malt-lymphoma judged refractory to hp-eradication by a minimum follow-up of 12 months after successfulhp-eradication will be included in the study. patients with gastric malt lymphoma and no evidence of hp-infection may be enrolled immediately * ann arbor stage i-iv * in case of prior treatment with rituximab, the presence of cd20 on lymphoma cells must have been demonstrated before inclusion in the trial. * ecog performance status of 0,1 or 2 * patient must be able to take aspirin daily as prophylactic anticoagulation (patients intolerant to asa may use warfarin or low molecular weight heparin exclusion criteria selected: * lymphoma histology other than malt lymphoma or malt lymphoma with a diffuse large cell lymphoma ("high grade lymphoma") - component * use of any investigational agent within 28 days prior to initiation of treatment with lenalidomide * history of malignancy other than squamous cell carcinoma, basal cell carcinoma of the skin or carcinoma in situ of the cervix within the last 5 years * major surgery, other than diagnostic surgery, within the last 4 weeks * evidence of cns involvement * a history of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant and adversely affecting compliance to study drugs * severe peripheral polyneuropathy * clinically significant cardiac disease or myocardial infarction within the last 6 months * known hypersensitivity to thalidomide or lenalidomide or rituximab

Keywords: malt lymphoma lenalidomide rituximab agmt